Effect of Intrathecal Lipophilic Opioids on the Incidence of Shivering in Women Undergoing Cesarean Delivery after Spinal Anesthesia: A Systematic Review and Bayesian Network Meta-analysis of Randomized Controlled Trials.

CURRENT STATUS: UNDER REVIEW

BMC Anesthesiology  •  BMC Series

Yamini Subramani
Western

Yamini.Subramani@lhsc.on.ca Corresponding Author

Mahesh Nagappa
Western University

Kamal Kumar
Western University

Lee-Anne Fochesato
Western University

Moaz Bin Yunus Chohan
Western University

YunFei Zhu
Western University

Kevin Armstrong
Western University

Sudha (Indu) Singh
Western University

10.21203/rs.3.rs-25731/v1

SUBJECT AREAS

Anesthesiology & Pain Medicine
Abstract

Background

Shivering is a common side effect in women having cesarean delivery (CD) under spinal anesthesia. It may be bothersome and can also interfere with perioperative monitoring. The intrathecal (IT) addition of a lipophilic opioid to local anesthetics has been shown to decrease the incidence of shivering in several studies in literature.

Objective

We performed this meta-analysis to evaluate the effects of intrathecal lipophilic opioids in preventing the incidence of shivering in patients undergoing CD.

Methods

This review was planned according to the PRISMA for Network Meta-Analysis (PRISMA-NMA) guidelines. An English literature search of multiple electronic databases was conducted. We included randomized controlled trials (RCTs) that reported on the incidence of shivering, with study groups receiving either IT fentanyl, sufentanil, or meperidine in women undergoing CD under spinal anesthesia. Quality of the studies was assessed using the modified oxford scoring system. Dichotomous data were extracted and summarized using Odds Ratio (OR) with 95% Credible intervals (CrI) using random-effects modeling. Statistical analysis was conducted using R studio version 1.0.153 - Inc.

Results

Twenty-one studies consisting of 1433 patients (Control group: 590 patients in twenty-one studies; Fentanyl group:199 patients in seven studies; Sufentanil group: 156 patients in five studies; Meperidine group: 488 patients in ten studies) met inclusion criteria for intrathecal lipophilic opioids to prevent the incidence of shivering in women undergoing cesarean delivery under spinal anesthesia. Methodological validity scores ranged from 3 to 7. The bayesian mixed network estimate showed the incidence of shivering was significantly lower with IT fentanyl (Pooled Odds Ratio (OR): 0.13; 95% Credible Interval (CrI): 0.04 to 0.35; P = 0.0004) and IT meperidine (OR: 0.12; 95% CrI: 0.05 to 0.29; P < 0.00001), but not with IT sufentanil (OR: 0.37; 95% CrI: 0.11 to 1.22; P = 0.23). The IT fentanyl group had a significantly lower incidence of intraoperative discomfort (RR: 0.19; 95% CI: 0.10–0.35; P < 0.00001), The IT sufentanil group had a significantly higher incidence of pruritus (RR: 6.18; 95% CI:
The IT Meperidine group had a significantly lower incidence of intraoperative discomfort (2.7% vs. 13.6%; RR: 0.22; 95% CI: 0.09–0.55; P = 0.001), but there was a significant increase in nausea and vomiting (IT meperidine group vs. Control group: 42.7% vs. 19.4%; RR: 2.56; 95% CI: 1.14–5.75; P = 0.02). Meta-regression analysis based on the opioid dose and quality of the study did not impact the final inference of our result.

**Conclusion**

IT fentanyl significantly decreased the incidence of shivering in women undergoing CD under spinal anesthesia without increasing maternal adverse events, confirming that routine use in this patient population is a good choice. IT sufentanil did not decrease the incidence of shivering. IT meperidine also decreased the incidence and severity of shivering, but it was associated with significant nausea and vomiting.

**Background**

Cesarean delivery is one of the most common operations performed. It is routinely carried out under spinal anesthesia using a combination of local anesthetics and opioids. Intrathecal (IT) addition of a lipophilic opioid to local anesthetic reduces the dose of local anesthetic, shortens the onset of block, markedly improves the quality of anesthesia, prolongs the duration of analgesia and also decreases the incidence of shivering.\(^1\)

Shivering occurs in up to 85% of patients undergoing cesarean delivery under spinal anaesthesia.\(^2,3\) The etiology of shivering likely involves multiple mechanisms. Pregnant patients have high circulating concentrations of progesterone which may account for decreased shivering thresholds. Neuraxial anesthesia probably impairs thermoregulation by producing peripheral vasodilatation as a result of the associated sympathetic blockade. This causes increased heat loss through the skin, resulting in an outflow of heat from the core to the periphery. Moreover, it also alters central nervous system responses by decreasing vasoconstriction and increasing sweating thresholds.\(^4\) Shivering is associated with an increased oxygen consumption up to 600% and increased CO\(_2\) production, a rise in blood pressure (BP) which can lead to serious hemodynamic effects in patients with compromised cardiopulmonary function. Shivering may also interfere with non-invasive patient monitoring.
disrupting care in the perioperative period.² Thus, prevention or treatment of shivering is an important clinical goal.

Common treatment regimens for shivering include increasing the body temperature, physical warming, increasing the operating room temperature, and using various medications such as clonidine, meperidine, fentanyl and morphine.⁵,⁶ Sufentanil, fentanyl and meperidine in decreasing order of lipid solubility are used as adjuvants for spinal anesthesia in patients undergoing cesarean delivery. Several randomized controlled studies investigated the effect of these opioids on the incidence of the shivering. However, inconsistencies in the results impeded meaningful conclusions. Therefore, we performed this systematic review and network meta-analysis (SRNMA) to evaluate the effects of the multiple lipophilic neuraxial opioids on the incidence of shivering in women having cesarean delivery under spinal anesthesia.

Methods

This meta-analysis was planned in accordance with the PRISMA-NMA guidelines (Preferred Reporting Items for Systematic Reviews for Network Meta-Analysis).

**Study Selection criteria**

A systematic search was performed for full reports of randomized controlled trials (RCT) that reported on the incidence of shivering in patients undergoing cesarean delivery under spinal anesthesia with IT lipophilic opioids such as fentanyl, sufentanil and meperidine. Relevant trials had to report the incidence of shivering in both the intervention and control groups. Any studies without data on control group were excluded from the analysis. The spinal anesthetic technique should have been standardized for both the treatment and control groups and should have included the administration of IT lipophilic opioids.

Literature Search: The following databases were systematically searched for relevant studies in English language by an expert librarian: PubMed, Medline, Embase, Cochrane Central Register of Controlled Trials, Web of Science, Scopus and CINAHL. The search was conducted from 1946 to October 2019. Additional studies were identified from the reference list of retrieved reports. Mesh keywords used in the search were “prevention”, “incidence”, “shivering”, “severity”, “intrathecal”,


“spinal”, “neuraxial”, “fentanyl”, “sufentanil”, “meperidine”, “lipophilic opioids”, “obstetric patients”, “parturients”, “caesarian section”, “cesarean delivery.” Data from abstracts, letters, retrospective trials, case reports and unpublished data were not considered and were excluded from the analysis.

Study retrieval - Two investigators (YS and KK) independently reviewed the search results in a stepwise manner. Relevant studies were first selected by title review of the search results. Abstracts of the selected studies were screened to determine if the inclusion/exclusion criteria were fulfilled. Then, the full text of the selected manuscript was considered and pertinent information was collected. In case of discrepancies, senior author (I.S) was consulted to resolve the issues.

Data Collection: A data collection form was used to collect the following data: (i) study ID; (ii) drug and dose of IT opioid [Fentanyl, Sufentanil and meperidine]; (iii) therapeutic allocation and sample size in each group; (iv) Primary outcome: outcome measures including the incidence of shivering; (v) secondary outcomes: incidence of side effects such as hypotension, intraoperative discomfort, pruritus, nausea and vomiting.

**Study quality assessment**

The articles meeting the inclusion criteria were scored independently by two authors (YS and KK) for methodological quality, based on the modified oxford score to determine the various risks of bias. The key domains assessed were (1) Randomization; (2) Concealment of allocation; (3) Double blinding; (4) Flow of patients.

**Statistical Analysis**

Network Meta-analysis (NMA): We conducted a network meta-analysis to permit comparison of multiple intrathecal lipophilic opioids across a network of trials within the same or very similar patient population: i.e. direct and indirect data were combined to try to estimate the most effective opioid to prevent the incidence of shivering. Analyses were undertaken using Bayesian random-effects models via Monte Carlo Markov Chain (MCMC) simulations with non-informative prior distributions. Analyses was performed using the R studio version 1.0.153 – Inc.

Crude data (Dichotomous data) was extracted from the individual studies and summarized as Odds Ratio (OR) with 95% credible intervals (CrI). The data for the individual groups was collected and then
pooled across groups using bayesian random-effects modeling. Continuity correction was done for those cells which had zero as the outcome. Two tailed P < 0.05 was considered statistically significant. For the direct data, the meta-regression and sensitivity analysis of the various subgroups was done to measure the impact of the various doses of IT opioids and quality of the studies on the incidence of shivering. Heterogeneity across studies was investigated for each group by chi-square test and calculating $I^2$.

**Quality of evidence in the network meta-analysis**

The level of confidence in each of the intrathecal opioid effect, estimated by the network meta-analysis, was assessed by using the CINeMA frame work $^9$ and GRADE approach. $^{10}$ The equality of evidence in each opioid effect was assessed for study limitation, indirectness, imprecision, inconsistency (heterogeneity and incoherence) and publication bias. Overall, certainty of the evidence was assessed using the GRADE approach. The study protocol is included in the supplementary file S1.

**Results**

Twenty-one potentially relevant articles were identified from 115 citations. Twenty-one studies consisting of 1433 patients (Control group: 590 patients in twenty-one studies; Fentanyl group: 199 patients in seven studies $^{11-17}$; Sufentanil group: 156 patients in five studies $^{18-22}$; Meperidine group: 488 patients in ten studies $^{15,23-31}$) contained data regarding the effect of IT opioids on shivering (Flow chart: Figure 1).

Table 1a and 1b summarises the systematic review of the effects of IT fentanyl, sufentanil and meperidine on shivering in women undergoing cesarean delivery. Methodological validity scores determined by modified oxford score ranged from 3 to 7.

**Network meta-analysis (NMA)**

A total of twenty-one studies and three interventions (fentanyl, sufentanil and meperidine) with four comparison groups were included in the network meta-analysis. Six pairwise comparison and four direct comparisons were done in the network meta-analysis. Table 2 summarises the data on the effect of intrathecal opioids on the incidence of shivering. Out of the twenty-one studies with 1433
patients, 199 patients received the fentanyl,\textsuperscript{11-17} 156 patients received the sufentanil,\textsuperscript{18-22} 488 patients received meperidine\textsuperscript{15,23-31} and 590 patients in the control group.

Table 2 provides the effect estimates of direct, indirect and mixed network meta-analysis with quality of evidence rating according to the GRADE approach. Figure 2 displays the network diagram comparing the various intrathecal lipophilic opioids to prevent incidence of shivering in women undergoing cesarean delivery. Supplementary file S2 and S3 show the contribution matrix and league table for comparison of all classes of drugs

\textbf{Fentanyl:} Data on the incidence of shivering with IT fentanyl (7 RCTs, n=199 patients) were available in all the studies.\textsuperscript{11-17} The mixed evidence from the network meta-analysis showed that the incidence of shivering was significantly lower in the IT fentanyl group compared to the control group [IT Fentanyl vs. Control group: 22.11\% vs. 51.94\%; Pooled Odds Ratio (OR): 0.13; 95\% Credible Interval (CrI): 0.04 to 0.35; p = 0.0004]. The funnel plot and influential analysis on the direct data identified Sadegh et al.\textsuperscript{2003} as the outlier and contributed the maximum heterogeneity to the end estimate. When this study was excluded and summary estimates were recalculated, the end estimate increased to 0.51 (0.36 to 0.71); P<0.0001 and heterogeneity decreased to zero (not shown in the figure). The Begg’s test (P=0.089) and Egger regression test (P=0.2077) did not show any evidence of publication bias. Fail safe N test showed 113 studies required to increase the p value to more than alpha (>0.05), indicating the absence of the publication bias (not shown in the figure). Fentanyl was administered in the dose range of 7.5 to 25 microgram and there was no difference in the outcomes across this dose range (Coefficient -0.043; 95\% CI: -0.0963 to 0.0103; P = 0.1139).

\textbf{Sufentanil:} Data on the incidence of shivering with IT sufentanil (5 RCTs, n=156 patients) were available in all the studies.\textsuperscript{18-22} The mixed evidence from the network meta-analysis showed that the incidence of the shivering was not significantly lower with the IT sufentanil when compared to the control group. (IT Sufentanil vs. Control group: 23.71\% vs. 45.28\%; OR: 0.37; 95\% CrI: 0.11 to 1.22; P = 0.23). Metaregression analysis based on the IT sufentanil dose, did not change the final inference of the result (Coefficient 0.0919; 95\% CI: -0.2495 to 0.4333; P = 0.5977)
Meperidine: Data on the incidence of shivering with IT meperidine were available in all the 10 studies. 15,23–31 The mixed evidence from the network meta-analysis showed that the incidence of shivering was lower in the meperidine group compared to the control group (IT Meperidine vs. Control group: 15% vs. 44.2%; OR: 0.12; 95% Crl: 0.05 to 0.29; P < 0.00001). For the direct data, the Begg’s test (P = 0.7544) and Egger regression test (P=0.1628) did not show any evidence of publication bias. Fail safe N test showed 85 studies required to increase the p value to more than alpha (>0.05), indicating the absence of the publication bias. Meperidine was used in the dose range of 5-35 mg and there was no difference in the outcomes across this dose range (Coefficient -0.0215; 95% CI: -0.0649 to 0.0219; P=0.3314). Metaregression and sensitivity analysis based on the quality of the study for the various subgroups slightly changed the end estimate, but did not change the final inference of our results (Table 3).

Side effects:

IT Fentanyl: The IT fentanyl group had a significantly lower incidence of intraoperative discomfort (IT fentanyl group vs. Control group: 6.89% vs. 34%; RR: 0.19; 95% CI: 0.10-0.35; P < 0.00001), but there was no significant difference in other maternal adverse events like pruritus (IT fentanyl group: 38.14% vs. 18.79%; RR: 2.03; 95% CI: 0.82-5.05; P = 0.13), nausea and vomiting (IT fentanyl group vs. Control group: 39.10% vs. 58.20%; RR: 0.66; 95% CI: 0.42-1.05; P = 0.08) and hypotension (IT fentanyl group: 43.57% vs. 54.47%; RR: 0.93; 95% CI: 0.78-1.12; P = 0.45) compared to the control group.

IT Sufentanil: The IT sufentanil group had a significantly higher incidence of pruritus (IT sufentanil vs. Control group: 20.87% vs. 2.12%; RR: 6.18; 95% CI: 1.18-32.46; P = 0.03), but there was no significant difference in other maternal adverse events like hypotension (IT sufentanil vs. Control group: 40.51% vs. 55.46%; RR: 0.74; 95% CI: 0.37-1.47; P = 0.39), nausea and vomiting (IT sufentanil group vs. Control group: 28.44% vs. 35.29%; RR: 0.83; 95% CI: 0.53-1.29; P = 0.40). IT sufentanil did not significantly decrease the intraoperative discomfort compared to the control group (IT sufentanil group vs. Control group: 36.84% vs. 59.09%; RR: 0.62; 95% CI: 0.31-1.24; P = 0.18).

IT Meperidine: The IT Meperidine group had significantly lower incidence of intraoperative
discomfort (IT meperidine group vs. Control group: 2.7% vs. 13.6%; RR: 0.22; 95% CI: 0.09-0.55; P = 0.001) compared to the control group. There was a significant increase in nausea and vomiting (IT meperidine group vs. Control group: 42.7% vs. 19.4%; RR: 2.56; 95% CI: 1.14-5.75; P = 0.02), but there was no significant difference in other maternal adverse events like hypotension (IT meperidine group vs. Control group: 46.9% vs. 41.8%; RR: 0.96; 95% CI: 0.67-1.37; P = 0.82) and pruritus (IT meperidine group vs. Control group: 18.9% vs. 6%; RR: 0.63; 95% CI: 0.82-3.24; P = 0.17) between the two groups.

**Quality of the evidence in network estimates:**

Supplementary file S4 and S5 shows the rankogram and various domains examined to assess the quality of evidence in the network meta-analysis. Most of the included studies in the network meta-analysis were randomized double blind controlled studies with no, or some concerns in the study limitation. To assess the imprecision, effect estimates of the relative treatments lower than 0.95 and greater than 1.05 were considered to be clinically significant. The data were collected from different studies, across different countries, at varying time intervals and the network model showed some degree of incoherence ($c^2$ statistics: 0.336; $d(f)$: 2; p value: 0.846). The estimated value of between-study variance for the network meta-analysis is 0.412 indicating some heterogeneity and consistency in the network model. Overall, some of the comparisons were rated down for imprecision, heterogeneity and incoherence (inconsistency), thus the quality of the evidence for the effect estimates was low according to the GRADE approach.

**Discussion**

In this systematic review evaluating the effects of lipophilic opioids to prevent or reduce shivering in patients having spinal anesthesia for cesarean delivery, fentanyl was found to be more effective than sufentanil and meperidine. IT fentanyl (7.5–25 mcg) was found to decrease the incidence and severity of shivering as well as to improve the quality of spinal anesthesia in women having CD. Fentanyl is a highly ionized, lipophilic µ-receptor agonist. When it is administered intrathecally, the unionized component is rapidly transferred into the spinal cord. IT fentanyl used with bupivacaine, in doses of 15 microgram has been shown to be effective in prolonging the duration of analgesia, and also exerts
an anti-nausea effect in such small doses. This is probably due to decreased nociceptive stimulation from peritoneal manipulation and uterine exteriorization due to augmented quality of spinal block caused by fentanyl. The reduction of shivering may be attributable to the effect of fentanyl that was added into the subarachnoid space on the thermo-regulator and spinal affect afferent thermal inputs at the spinal cord. It is shown that fentanyl can reduce the intensity and severity of shivering up to 3 hours after spinal anesthesia, including the time before delivery of the baby. This reduces the requirement of intravenous medications to treat shivering before delivery, thereby decreasing any harmful effects of medications on the baby. The main detriment of preventing shivering is the fall in body temperature as shivering is a protective autonomic response against hypothermia. However, fentanyl lowered the core temperature for only 2 hours, with return to baseline temperature in the third hour, without any harmful effects on the patient.

We found that addition of IT fentanyl was associated with lowest incidence of intraoperative discomfort due to increase in the quality of analgesia. The incidence of pruritus with the administration of opioid into the subarachnoid space was reported to be 67% for fentanyl, and 80% for sufentanil. But, several studies have shown that there was no increase in the incidence of pruritus with IT fentanyl doses less than 50 microgram. Also, the pruritus associated with IT fentanyl and sufentanil is transient and resolves rapidly, usually without any need for treatment. Sufentanil is highly lipophilic with a higher affinity to opioid receptors, with a less cephalad spread and a much higher analgesic potency when compared with fentanyl or morphine. It is well accepted for use in spinal anesthesia together with local anesthetics for caesarean delivery. The combination of hyperbaric ropivacaine 10 mg with sufentanil 5 μg produced effective spinal anaesthesia for caesarean delivery with significantly less hypotension, vomiting and shivering, shorter duration of motor blockade and longer lasting analgesia than hyperbaric ropivacaine15 mg. Our results show that IT sufentanil was not effective in decreasing and severity of shivering in patients undergoing CD, but this meta-analysis was limited by the small number of available studies.
evaluating this outcome. Nevertheless, a previous metanalysis on IT and epidural sufentanil had similar findings and the authors postulated that the low dose range of IT and epidural sufentanil used (1.5-20 µg) may not be effective in decreasing shivering.

Meperidine is an opioid with intermediate lipid solubility and is unique in having local anesthetic properties. It has been used as a sole agent for spinal anesthesia for cesarean delivery. It prolongs postoperative analgesia up to 4 hours, which is much less compared to IT morphine (upto 24 hours). An incidence of pruritus of 10.7-32% has been reported with the use of ≥ 50 mg of IT meperidine, which is much lower than IT morphine. Meperidine is shown to be effective against shivering and the ant shivering effect of intravenous meperidine is attributed to its role in increasing the shivering threshold due to its effect on the Kappa opioid receptor. Possible suggested mechanisms for the antishivering effect of meperidine include k-opioid receptor activity, anticholinergic action, biogenic monoamine reuptake inhibition, NMDA receptor antagonism, or stimulation of alpha 2-adrenoceptors, and possibly modulating the heat loss caused by vasodilatation after spinal anesthesia. Meperidine slightly increases the threshold for sweating, significantly decreases the threshold for vasoconstriction, and reduces the threshold for shivering. We found that IT meperidine was associated with nausea and vomiting, which limits its clinical efficacy.

Limitations
The doses of IT fentanyl, sufentanil and meperidine differed among the studies, which is a limitation of this systematic review, although the meta-regression ruled out the effect of the varying doses on our primary outcome. Overall, this systematic review and met-analysis provides the best summary of the effect of the IT lipophilic opioids on shivering after cesarean delivery.

Conclusion
IT fentanyl significantly decreased the incidence and severity of shivering in women undergoing cesarean delivery under spinal anesthesia without increasing maternal adverse events, indicating that their routine use in this patient population should be considered. IT sufentanil did not decrease the incidence or severity of shivering. IT meperidine also decreased the incidence and severity of
shivering, but it was associated with significant nausea and vomiting.

**Abbreviations**

BP
Blood Pressure
CD
Caesarean delivery
CrI
Credible Intervals
IT
Intrathecal
MCMC
Monte Carlo Markov Chain
NMA
Network Meta-analysis
OR
Odds Ratio
PRISMA-NMA
Preferred Reporting Items for Systematic Reviews for Network Meta-Analysis.
RCT
Randomized Controlled Trials
SRNMA
systematic review and network meta-analysis

**Declarations**

**Ethics approval and consent to participate:** Not required for this study.

**Consent for publication:** Not required for this study.

**Competing interests:** Explained with every authors name and credentials but none of the authors declared any competing interests.

**Funding:** This study is supported by Department of Anesthesia and Perioperative Medicine, Western University, London, Ontario, Canada. The office space, library, printing and computer facilities were used from the department.

**Author’s contributions:** Author’s contributions have been described along with author names and titles.
Acknowledgment: We thank Brie McConnell MLIS (Media and Information Manager, London Health Science Centre, Western University) for her assistance with the literature search.

Availability of data and material: File named SRNMA protocol has been uploaded along with the manuscript which contains supplementary material.

References
1. Lee YY, Ngan Kee WD, Muchhal K, Chan CK. Randomized double-blind comparison of ropivacaine-fentanyl and bupivacaine-fentanyl for spinal anaesthesia for urological surgery. Acta Anaesthesiol Scand. 2005;49:1477–82.

2. Kranke P, Eberhart LHJ, Roewer N, Tramèr MR. Postoperative shivering in children: a review on pharmacologic prevention and treatment. Paediatr Drugs. 2003;5:373–83.

3. Kranke P, Eberhart LH, Roewer N, Tramèr MR. Single-Dose Parenteral Pharmacological Interventions for the Prevention of Postoperative Shivering: A Quantitative Systematic Review of Randomized Controlled Trials. Anesth Analg. 2004;99:718–27.

4. Sessler DI. Temperature Monitoring and Perioperative Thermoregulation. Anesthesiology. 2008;109:318–38.

5. Alfonsi P, Hongnat JM, Lebrault C, Chauvin M. The effects of pethidine, fentanyl and lignocaine on postanaesthetic shivering. Anaesthesia. 1995;50:214–7.

6. Horn E-P, Werner C, Sessler DI, Steinfath M, am Esch JS. Late Intraoperative Clonidine Administration Prevents Postanesthetic Shivering After Total Intravenous or Volatile Anesthesia. Anesth Analg. 1997;84:613–7.

7. Jadad AR, Moore RAA, Carroll D, Jenkinson C, Reynolds DJJM, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17:1-12.

8. Bafeta A, Trinquart L, Seror R, Ravaud P. Reporting of results from network meta-analyses: methodological systematic review. BMJ. 2014;348:1741-1.
9. Salanti G, Giovane C, Del, Chaimani A, Caldwell DM, Higgins JPT. Evaluating the Quality of Evidence from a Network Meta-Analysis. Tu Y-K, ed. PLoS One 2014;9:e99682.
10. Puhan MA, Schunemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, Kessels AG, Guyatt GH. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630–0.
11. Palmer CM, Voulgaropoulos D, Alves D. Subarachnoid fentanyl augments lidocaine spinal anesthesia for cesarean delivery. Reg Anesth. 1995;20:389–94.
12. Chu CC, Shu SS, Lin SM, Chu NW, Leu YK, Tsai SK, Lee TY. The effect of intrathecal bupivacaine with combined fentanyl in cesarean section. Acta Anaesthesiol Sin. 1995;33:149–54.
13. Kang FC. Subarachnoid fentanyl with diluted small-dose bupivacaine for cesarean section delivery. Acta Anaesthesiol Sin. 1998;36:207–14.
14. Techanivate A, Rodanant O, Tachawattanawisal W, Somsiri T. Intrathecal Fentanyl for Prevention of Shivering in Cesarean section. J Med Assoc Thail. 2005;88:1214–21.
15. Han JW, Kang HS, Choi SK, Park SJ, Park HJ, Lim TH. Comparison of the Effects of Intrathecal Fentanyl and Meperidine on Shivering after Cesarean Delivery under Spinal Anesthesia. Korean J Anesth. 2007;52:657–62.
16. Sadegh A, Tazeh-Kand NF, Eslami B. Intrathecal fentanyl for prevention of shivering in spinal anesthesia in cesarean section. Med J Islam Repub Iran. 2012;26:85–9.
17. Agrawal A, Asthana V, Sharma J, Gupta V. Efficacy of lipophilic vs lipophobic opioids in addition to hyperbaric bupivacaine for patients undergoing lower segment caesarean section. Anesth Essays Res. 2016;10:420–4.
18. Lin BC. The maternal and fetal effects of the addition of sufentanil to 0.5% spinal bupivacaine for cesarean delivery. Acta Anaesthesiol Sin. 1998;36:143–8.
19. Qian XW, Chen XZ, Li DB. Low-dose ropivacaine-sufentanil spinal anaesthesia for caesarean delivery: a randomised trial. Int J Obstet Anesth. 2008;17:309-14.

20. Chen X, Qian X, Fu F, Lu H, Bein B. Intrathecal sufentanil decreases the median effective dose (ED50) of intrathecal hyperbaric ropivacaine for caesarean delivery. Acta Anaesthesiol Scand. 2010;54:284-90.

21. Figueiredo Locks G, De. Incidence of Shivering after Cesarean Section under Spinal Anesthesia with or without Intrathecal Sufentanil: A Randomized Study. Rev Bras Anestesiol. 2012;62:676-84.

22. Abdollahpour A, Azadi R, Bandari R, Mirmohammadkhani M, Agrawal A, Asthana V, Sharma JP, Gupta V, Anaraki AN, Mirzaei K, Bogra J, Arora N, Srivastava P, Chen XZ, Qian XW, Fu F, Lu H, Bein B, Chu CC, Shu SS, Lin SM, Chu NW, Leu YK, Tsai SK, Lee TY, Figueiredo Locks G de, Hong JY, Lee IH, Kang FC, Tsai YC, et al. Effects of Adding Midazolam and Sufentanil to Intrathecal Bupivacaine on Analgesia Quality and Postoperative Complications in Elective Cesarean Section. Acta Anaesthesiol Sin. 2012;10:309-14.

23. Yu S-C, Ngan Kee WD, Kwan ASK. Addition of meperidine to bupivacaine for spinal anaesthesia for Caesarean section †. Br J Anaesth. 2002;88:379-83.

24. Roy J-D, Girard M, Drolet P. Intrathecal Meperidine Decreases Shivering During Cesarean Delivery Under Spinal Anesthesia. Anesth Analg. 2004;98:230-4.

25. Anaraki AN, Mirzaei K. The effect of different intrathecal doses of meperidine on shivering during delivery under spinal anesthesia. Int J Prev Med. 2012;3:706-12.

26. Hong J-Y, Lee IH. Comparison of the effects of intrathecal morphine and pethidine on shivering after Caesarean delivery under combined-spinal epidural anaesthesia*. Anaesthesia. 2005;60:1168-72.

27. Imarengiaye CO, Asudo FD, Akpoguado DD, Akhideno II, Omoifo CE, Ogunsakin AT.
Subarachnoid bupivacaine and pethidine for caesarean section: assessment of quality of perioperative analgesia and side effects. Niger Postgrad Med J. 2011;2:18-22.

28. Khan ZH, Zanjani AP, Makarem J, Samadi S. Antishivering effects of two different doses of intrathecal meperidine in caesarean section: a prospective randomised blinded study. Eur J Anaesthesiol. 2011;28:202-6.

29. Rastegarian A, Ghobadifar MA, Kargar H, Mosallanezhad Z. Intrathecal Meperidine Plus Lidocaine for Prevention of Shivering during Cesarean Section. Korean J Pain. 2013;26:379-86.

30. Shami S, Nasseri K, Shirmohammadi M, Sarshivi F, Ghadami N, Ghaderi E, Pouladi M, Barzanji A. Effect of low dose of intrathecal pethidine on the incidence and intensity of shivering during cesarean section under spinal anesthesia: a randomized, placebo-controlled, double-blind clinical trial. Drug Des Devel Ther. 2016;10:3005–12.

31. Atalay C, Aksoy M, Aksoy A, Dogan N, Kürsad H. Combining Intrathecal Bupivacaine and Meperidine during Caesarean Section to Prevent Spinal Anaesthesia-Induced Hypotension and other Side-Effects. J Int Med Res. 2010;38:1626-36.

32. Dahl JB, Jeppesen IS, Jørgensen H, Wetterslev J, Møiniche S. Intraoperative and postoperative analgesic efficacy and adverse effects of intrathecal opioids in patients undergoing cesarean section with spinal anesthesia: a qualitative and quantitative systematic review of randomized controlled trials. Anesthesiology. 1999;91:1919–27.

33. Reich A, Szepietowski JC. Opioid-induced pruritus: An update. Clin Exp Dermatol. 2010;35:2–6.

34. Hunt CO, Naulty JS, Bader AM, Hauch MA, Vartikar JV, Datta S, Hertwig LM, Ostheimer GW. Perioperative Analgesia with Subarachnoid Fentanyl-Bupivacaine for Cesarean Delivery. Anesthesiology. 1989;71:535-40.
35. Dahlgren G, Hultstrand C, Jakobsson J, Norman M, Eriksson EW, Martin H. Intrathecal Sufentanil, Fentanyl, or Placebo Added to Bupivacaine for Cesarean Section. Anesth Analg. 1997;85:1288–93.

36. Reuben SS, Dunn SM, Duprat KM, O’Sullivan P, O’Sullivan P. An Intrathecal Fentanyl Dose-Response Study in Lower Extremity Revascularization Procedures. Anesthesiology 1994;81:1371–5.

37. Leysen JE, Gommeren W, Niemegeers CJE. [3H]sufentanil, a superior ligand for μ-opiate receptors: Binding properties and regional distribution in rat brain and spinal cord. Eur J Pharmacol. 1983;87:209–25.

38. Grass JA, Sakima NT, Schmidt R, Michitsch R, Zuckerman RL, Harris APA, Randomized. Double-Blind, Dose-Response Comparison of Epidural Fentanyl Versus Sufentanil Analgesia After Cesarean Section. Anesth Analg. 1997;85:365–71.

39. Olofsson C, Nygards E-B, Bjersten A-B, Hessling A. Low-dose bupivacaine with sufentanil prevents hypotension after spinal anesthesia for hip repair in elderly patients. Acta Anaesthesiol Scand. 2004;48:1240–4.

40. Feng LS, Hong G, Yan Z, Qiu LY, Liang LA. Intrathecal Sufentanil Does Not Reduce Shivering During Neuraxial Anesthesia: A Meta-Analysis. Med Sci Monit. 2016;22:258–66.

41. Johnson MD, Sevarino FB, Lema MJ. Cessation of Shivering and Hypothermia Associated with Epidural Sufentanil. Anesth Analg. 1989;68:70–1.

42. Ngan Kee WD. Intrathecal pethidine: Pharmacology and clinical applications. Anaesth Intensive Care 1998:26: 137–46.

43. Cheun JK, Kim AR. Intrathecal meperidine as the sole agent for cesarean section. J Korean Med Sci. 1989;4:135–9.

44. Kafle SK. Intrathecal meperidine for elective Caesarean section: a comparison with
45. Nguyen Thi TV, Orliaguet G,Ngu TH, Bonnet F. Spinal anesthesia with meperidine as the sole agent for cesarean delivery. Reg Anesth. 1994;19:386-9.

46. Abouleish E, Rawal N, Fallen K, Hernandez D. Combined Intrathecal Morphine and Bupivacaine for Cesarean Section. Anesth Analg. 1988;67:370-4.

47. Swart M, Sewell J, Thomas D. Intrathecal morphine for Caesarean section: an assessment of pain relief, satisfaction and side-effects. Anaesthesia. 1997;52:373-7.

48. Palmer CM, Emerson S, Volgoropolous D, Alves D. Dose-Response Relationship of Intrathecal Morphine for Postcesarean Analgesia. Anesthesiology. 1999;90:437-44.

49. Kato R, Shimamoto H, Terui K, Yokota K, Miyao H. Delayed respiratory depression associated with 0.15 mg intrathecal morphine for cesarean section: a review of 1915 cases. J Anesth. 2008;22:112-6.

50. Casey WF, Smith CE, Katz JM, O’Loughlin K, Weeks SK. Intravenous meperidine for control of shivering during Caesarean section under epidural anaesthesia. Can J Anaesth. 1988;35:128-33.

51. Ikeda T, Sessler DI, Tayefeh F, Negishi C, Turakhia M, Marder D, Bjorksten AR, Larson MD. Meperidine and Alfentanil Do Not Reduce the Gain or Maximum Intensity of Shivering. Anesthesiology. 1998;88:858-65.

52. Kurz M, Belani KG, Sessler DI, Kurz A, Larson MD, Schroeder M, Blanchard D. Naloxone. Meperidine Shivering Anesthesiology. 1993;79:1193-201.

53. Kang YG, Abouleish E, Caritis S. Prophylactic intravenous ephedrine infusion during spinal anesthesia for cesarean section. Anesth Analg. 1982;61:839-42.

54. Larsen J-J, Hyttel J. 5-HT-Uptake Inhibition Potentiates Antinociception Induced by Morphine, Pethidine, Methadone and Ketobemidone in Rats. Acta Pharmacol Toxicol (Copenh). 1985;57:214-8.
55. Takada K, Clark DJ, Davies MF, Tonner PH, Krause TKW, Bertaccini E, Maze M. Meperidine exerts agonist activity at the α 2B-adrenoceptor subtype. Anesthesiology. 2002;96:1420–6.

56. Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-d-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett. 1995;187:165–8.

57. Kurz A, Ikeda T, Sessler DI, Larson MD, Bjorksten AR, Christensen DECHERTM R. Meperidine Decreases the Shivering Threshold Twice as Much as the Vasoconstriction Threshold. Anesthesiology 1997;86:1046–54.

Tables

Table 1a: Effect of lipophilic opioids on incidence of shivering in women undergoing cesarean delivery after spinal anesthesia: A systematic review of randomized control trials in a tabular column

| Serial No. | Study reference | Study ID year [Country of origin] [Modified Oxford score-R/C/D/F] | Groups Drug & Dosage [Intrathecal administration] | Results |
|------------|-----------------|---------------------------------------------------------------|-------------------------------------------------|---------|
| 1          | 11Palmer et al.1995 [USA] [2/0/2/0] | Control Vs. Fentanyl (F) 15 mg | Group F (14) vs. Control (14) | Incidence: 0% vs. 14.28% Severity (Grades 3 and 4): NA Side Effects: Hypotension: 0 vs. 0 Pruritus: 7.14% vs. 28.57% Nausea and vomiting: 50% vs 92.85% Intraoperative discomfort: NA Respiratory depression: 0 vs. 0 |
| 2          | 20Chen et al.2010 [Germany] [2/0/2/2] | Control Vs. Sufentanil (S) 5 mg | Group S (32) vs. Control (32) | Incidence: 0% vs. 38% Severity (Grades 3 and 4): NA Side Effects: Hypotension: 19% vs. 38% Pruritus: 31% vs. 0% Nausea and vomiting: 31% vs. 52% Intraoperative discomfort: NA Respiratory depression: 0 vs. 0 |
| 3          | 22Abdollahpour et al.2015 [Iran] [2/0/2/2] | Control Vs. Sufentanil (S) 1.5 mg | Group S (25) vs. Control (25) | Incidence: 48% vs. 40% Severity (Grades 3 and 4): NA Side Effects: Hypotension: 64% vs 84% Pruritus: NA Nausea and vomiting: 64% vs. 52% Intraoperative discomfort: NA Respiratory depression: NA |
| 4          | 15Han et al.2007 [Korea] [2/0/2/0] | Control Vs. Fentanyl (F) 12.5 mg | Group F (20) vs. Control (20) | Incidence: 30% vs. 65% Severity (Grades 3 and 4): - 10% vs. 35% Side Effects: Hypotension: NA Pruritus: NA Nausea and vomiting: NA |
| Study Reference | Country | Study Design | Intervention | Comparison | Outcomes |
|-----------------|---------|--------------|--------------|------------|----------|
| 5 Agrawal et al. 2016 | India | Control vs. Fentanyl (F) 25 mg | Group F (20) vs. Control (20) | Incidence: 10% vs. 30% | Intraoperative discomfort: NA, Respiratory depression: NA |
| 6 Sadegh et al. 2012 | Iran | Control vs. Fentanyl (F) 25 mg | Group F (40) vs. Control (40) | Incidence: 10% vs. 75% | Hypotension: 75% vs. 75%, Pruritus: 30% vs. 0% |
| 7 Qian et al. 2009 | China | Control vs. Sufentanil (S) 5 mg | Group S (40) vs. Control (40) | Incidence: 20% vs. 60% | Hypotension: 20% vs. 55% |
| 8 Locks et al. 2012 | Brazil | Control vs. Sufentanil (S) 2.5 mg | Group S (40) vs. Control (40) | Incidence: 32.5% vs. 62.5% | Hypotension: NA |
| 9 Techanivate et al. 2005 | Thailand | Control vs. Fentanyl (F) 20 mg | Group F (30) vs. Control (30) | Incidence: 20% vs. 50% | Hypotension: 36.7% vs. 50%, Pruritus: 66.66% vs. 40% |
| 10 Kang et al. 1998 | Taiwan | Control vs. Fentanyl (F) 25 mg | Group F (15) vs. Control (15) | Incidence: 0% vs. 33.3% | Hypotension: 20% vs. 40% |
| 11 Chu et al. 1995 | China | Control vs. Fentanyl (F) 7.5 mg, Fentanyl (F) 10 mg, Fentanyl (F) 12.5 mg, Fentanyl (F) 15 mg | Group F 7.5 (15) vs. F 10 (15) vs. F 12.5 Control (15) | Incidence: 66.7% vs. 46.6% vs. 33.3% vs. 21 | Hypotension: 26.6% vs. 40% vs. 26.6% vs. 26.6% |
| 12 Lin et al. 1998 | China | Control vs. Sufentanil (S) 10 mg | Group S (19) vs. Control (22) | Incidence: 21% vs. 4.5% (4 vs. 1) | Hypotension: 89.47% vs. 57.89% (17 vs. 11) |

Incidence: % vs. % (N vs. N)
Modified Oxford Score varies from 0 to 7

Table 1b: Effect of Meperidine on incidence of shivering in women undergoing cesarean delivery after spinal anesthesia: A systematic review of randomized control trials in a tabular column

| Serial No. | Study Reference | Study ID [Country of origin] [Modified Oxford score-R/C/D/F] | Groups Drug, dosage (Intrathecal Administration) | Results |
|------------|----------------|-------------------------------------------------------------|-------------------------------------------------|---------|
| 1          | 23Yu et al.2002 [China] [2/1/2/2] | Control Vs. Meperidine (M) 10 mg | Group M (20) vs. Control (20) • Incidence: 15% vs. 40% • Severity (Grades 3 and 4): NA Side Effects: • Hypotension: 70% vs. 55% • Pruritus: 0 vs. 0 • Nausea and vomiting: 55% vs. 15% • Intraoperative discomfort: 0% vs. 10% • Respiratory depression: 0 vs. 0 |
| 2          | 28Khan et al.2011 [Iran] [2/0/2/2] | Control Vs. Meperidine (M1) 12.5 mg Meperidine (M2) 25 mg | Group M1 (24) vs. M2 (24) vs. Control (2) • Incidence: 20.83% vs. 4.16% vs. 58.33% • Severity (Grades 3 and 4): 0 vs. 0 vs. 16.66% Side Effects: • Hypotension: 50% vs. 45.8% vs. 41.7% • Pruritus: 0 vs. 0 vs. 0 • Nausea and vomiting: 25% vs. 75% vs. 4.2% • Intraoperative discomfort: NA • Respiratory depression: 0 vs. 0 vs. 0 |
| 3          | 31Atalay et al.2010 [Turkey] [2/0/2/2] | Control Vs. Meperidine (M1) 25 mg Meperidine (M2) 30 mg Meperidine (M3) 35 mg | Group M1 (20) vs. M2 (20) vs. M3 (20) Co • Incidence: 0% vs. 0% vs. 0% • Severity (Grades 3 and 4): NA Side Effects: • Hypotension: 20% vs. 30% vs. 55% vs. 65% • Pruritus: 10% vs. 35% vs. 45% vs. 0 • Nausea and vomiting: 25% vs. 45% vs. 75% • Intraoperative discomfort: 0 vs. 0 vs. 0 vs. 0 • Respiratory depression: 0 vs. 0 vs. 0 vs. 0 |
| 4          | 15Han et al.2007 [Korea] [2/0/2/0] | Control Vs. Meperidine (M) 12.5 mg | Group M (20) vs. Control (20) • Incidence: 20% vs. 65% • Severity (Grades 3 and 4): 5% vs. 35% Side Effects: NA |
| 5          | 26Hong et al.2005 [South Korea] [2/1/2/2] | Control Vs. Meperidine (M) 10 mg | Group M (30) vs. Control (30) • Incidence: 3.3% vs. 23.3% • Severity (Grades 3 and 4): 0% vs. 20% Side Effects: NA |
| 6          | 24Denis Roy et al.2004 [Canada] [2/0/2/0] | Control Vs. Meperidine (M) 0.2mg/kg (15 mg average) | Group M (20) vs. Control (20) • Incidence: 45% vs. 85% • Severity (Grades 3 and 4): 10% vs. 45% Side Effects: • Hypotension: NA • Pruritus: 0 vs. 0 • Nausea and vomiting: 0 vs. 0 |
|   | Reference            | Country            | Group Description                                                                 | Effect Size                                                                 |
|---|----------------------|--------------------|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------|
| 7 | Rastegarian et al. 2013 | [Iran] [2/1/2/2]   | Control Vs. Meperidine (M) 0.2mg/kg (15 mg average)                                | Group M (50) vs. Control 50  
  \- Incidence: 8% vs. 28%  
  \- Severity (Grades 3 and 4): 0% vs. 18%  
  **Side Effects:**  
  \- Hypotension: 14% vs 12%  
  \- Pruritus: 0 vs. 0  
  \- Nausea and vomiting: 18% vs. 0  
  \- Intraoperative discomfort: NA  
  \- Respiratory depression: 0 vs. 0 |
| 8 | Anaraki et al. 2012   | [Iran] [2/1/2/2]   | Control Vs. Meperidine (M1) 0.2mg/kg (15 mg average) Meperidine (M2) 0.3mg/kg (25 mg average) Meperidine (M3) 0.4mg/kg (30 mg average) | Group M1 (38) vs. M2 (38) vs. M3 (39) Co  
  \- Incidence: 37.5% vs. 27.5% vs. 15% vs. 47.5%  
  \- Severity (Grades 3 and 4): 17.5% vs. 7.5% vs. 17.6%  
  **Side Effects:**  
  \- Hypotension: NA  
  \- Pruritus: 28.21% vs. 38.46% vs. 48.72% vs. 30%  
  \- Nausea and vomiting: 15.4% vs. 25.9% vs. 17.6%  
  \- Intraoperative discomfort: 4.6% vs. 4.8% vs. 4.3%  
  \- Respiratory depression: 0 vs. 0 vs. 0 |
| 9 | Imarengiaye et al. 2011 | [Nigeria] [2/1/2/1] | Control Vs. Meperidine (M) 7.5 mg                                                | Group M (25) vs. Control (25)  
  \- Incidence: 0% vs. 4%  
  \- Severity (Grades 3 and 4): NA  
  **Side Effects:**  
  \- Hypotension: 40% vs. 8%  
  \- Pruritus: 0 vs. 0  
  \- Nausea and vomiting: 20% vs. 0%  
  \- Intraoperative discomfort: 0% vs. 16%  
  \- Respiratory depression: 0 vs. 0 |
| 10| Shami et al. 2016    | [Iran] [2/1/2/2]   | Control Vs. Meperidine (M) 5 mg  Meperidine (M) 10 mg                           | Group M5 (50) vs. Group M10 (50) vs. Control (50)  
  \- Incidence: 13% vs. 3% vs. 25% (26% vs. 6% vs. 3%)  
  \- Severity (Grades 3 and 4): 0 vs 0 vs. 1 (2%)  
  **Side Effects:**  
  \- Hypotension: 33 vs. 37 vs. 34 (66% vs. 74%)  
  \- Pruritus: 3 vs. 13 vs. 0 (6% vs. 26% vs. 0%)  
  \- Nausea and vomiting: 38 vs. 40 vs. 25 (76% vs. 50%)  
  \- Intraoperative discomfort: NA  
  \- Respiratory depression: NA |

R/C/D/F: Randomization (2)/Concealment of allocation (1)/Double blinding (2)/Flow of patients (2); NA: Not Available

**Modified Oxford Score** varies from 0 to 7

**Table 2:** Network meta-analysis: Estimates of direct effect, Indirect effect and mixed effect with quality ratings according to GRADE approach, for the incidence of shivering in women undergoing caesarean delivery with intrathecal lipophilic opioids.
### Table 3: Study Quality assessment: Meta-regression and sensitivity analysis

| Subgroups                  | Quality of study (No. of studies) | Point Estimate | 95% CI       | $i^2$ | Coeff (Std Error) |
|----------------------------|-----------------------------------|----------------|--------------|-------|------------------|
| **Fentanyl**               | Good (2)                          | 0.24           | 0.08 - 0.72  | 69%   | -0.50            |
|                            | Poor - moderate (5)                | 0.50           | 0.32 - 0.79  | 13%   |                  |
| **Sufentanil**             | Good (3)                          | 0.40           | 0.1 - 1.66   | 85%   | -0.98            |
|                            | Poor - moderate (2)                | 1.23           | 0.14 - 10.7  | 76%   |                  |
| **Low dose Meperidine**    | Good (7)                          | 0.41           | 0.27 - 0.61  | 26%   | -0.12            |
|                            | Poor - moderate (2)                | 0.46           | 0.28 - 0.75  | 8%    |                  |
| **High dose Meperidine**   | Good (3)                          | 0.10           | 0.01 - 1.0   | 81%   |                  |
|                            | Poor - moderate (0)                | -              | -            |       |                  |

CI: Confidence Interval. Study quality scores were obtained from the modified oxford scoring system.

Study was considered good when assigned score was equal or greater than 5 out of 7. P-values are based on random-effects model.

**Supplementary File**

- Supplementary file S1: Study protocol
- Supplementary file S2: Contribution Matrix
- Supplementary file S3: League Table
- Supplementary file S4: Rankogram with SUCRA
- Supplementary file S5: Quality of evidence in the network meta-analysis assessed in the following

OR: Odds ratio; CI: Confidence Interval; CrI: Credible interval; §: rated down for Indirectness; †: Contributing direct evidence of low quality; ‡: rated down for major concern in Imprecision; #: rated down for Heterogeneity; *: Statistically significant results.
domains, study limitation, imprecision, Heterogeneity, Incoherence, Indirectness, and final report.

Figures

Figure 1

Flowchart on the literature search.
Figure 2

Network diagram comparing the various classes of drugs. Evidence network of randomized trials comparing the effects of drugs to prevent shivering in women undergoing cesarean delivery with intrathecal lipophilic opioids. The size of the circle is proportional to the number of participants randomized to that treatment. Width of the lines is proportional to the number of trials for that comparison. The green line indicates the statistically significant results between the compared groups.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.
SRNMAProtocol.pdf